Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Linifanib||ABT-869|AL-39324||CSF1R Inhibitor 24 FLT3 Inhibitor 55 KIT Inhibitor 51 PDGFR-beta Inhibitor 13 VEGFR Inhibitor (Pan) 32||Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||hepatocellular carcinoma||not applicable||Linifanib||Phase II||Actionable||In a Phase II clinical trial, single-agent linifanib was found safe and efficacious in patients with advanced hepatocellular carcinoma (PMID: 22833179).||22833179|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|